Kakar et al Levy T, Walker S, Rochelle J, et al. 1999. Evaluation of biatrial pacing, right atrial pacing, and no pacing in patients with drug refractory atrial ﬁbrillation. Am J Cardiol, 84:426–9. Li-Saw-Hee FL, Lip GYH. 1998. Digoxin Revisted. Q JM, 91:259–64. Lim HS, Hamaad A, Lip GY. 2004. Clinical management of atrial ﬁbrillation —rate control versus rhythm control. Crit Care, 8:271–9. Lin HJ, Wolf PA, Kelly-Hayes M, et al. 1996. Stroke severity in atrial ﬁbrillation: the Framingham study. Stroke, 27: 1760–4 Lip GY, Edwards SJ. 2006. Stroke prevention with aspirin, warfarin and ximelgatran in patients with atrial ﬁbrillation: a systematic review and meta-analysis. Thromb Res, 118:321–33. Lip GY, Boos CJ. 2005. Antithrombotic therapy for atrial ﬁbrillation. Heart, 92:155–61. Lip GY, Tean KN, Dunn FG. 1994. Treatment of atrial ﬁbrillation in a district general hospital. Br Heart J, 71:92–5. Lip GY. 1995. Does atrial ﬁbrillation confer a hypercoagulable state? Lancet, 346:1313–14. Lip GY, Lane D, Van Walraven C, et al. 2006. Additive role of plasma von Willebrand factor levels to clinical factors for risk stratiﬁcation of patients with atrial ﬁbrillation. Stroke, 37:2294–300. Maragno I, Santostasi G, Gaion RM, et al. 1998. Low- and medium-dose diltiazem in chronic atrial ﬁbrillation: comparison with digoxin and correlation with drug plasma levels. Am Heart J, 116:385–92. Michael JA, Stiell IG, Agarwal S, et al. 1999. Cardioversion of paroxys- mal atrial ﬁbrillation in the emergency department. Ann Emerge Med, 33:379–87. Miyazaki S, Ito T, Suwa M, et al. 2001. Role of transesophageal echocar- diography in the prediction of thromboembolism in patients with chronic nonvalvular atrial ﬁbrillation. Jpn Circ J, 65:874–8. Morgan S, Mant D. 2002. Randomised trial of two approaches to screen- ing for atrial ﬁbrillation in UK generalpractice. Br J Gen Pract, 52:373–80. Murray ET, Fitzmaurice DA, McCahon D. 2004. Point of care testing for INR monitoring: where are we now? Br J Haematol, 127:373–8. Okcun B, Yigit Z, Arat A, 2004. Comparison of rate and rhythm control in patients with atrial ﬁbrillation and nonischemic heart failure. Jpn Heart J, 45:591–601. Okcun B, Yigit Z, Kucukoglu MS, et al. 2002. Predictors for maintenance of sinus rhythm after cardioversion in patients with nonvalvular atrial ﬁbrillation. Echocardiography, 19:351–7. Opolski G, Torbicki A, Kosior D, et al. 2003. Rhythm control versus rate control in patients with persistent atrial ﬁbrillation. Results of the HOT CAFE Polish Study. Kardiologia Polska, 59:1–16. Page RL, Wilkinson WE, Clair WK, et al. 1994. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial ﬁbrillation and parox- ysmal supraventricular tachycardia. Circulation, 89:224–7. Paraskevaidis IA, Dodouras T, Tsiapras D. 2005. Prediction of successful cardioversion and maintenance of sinus rhythm in patients with lone atrial ﬁbrillation. Chest, 127:488–94. Reiffel JA, Schwarzberg R, Murry M. 2005. Comparison of autotriggered memory loop recorders versus standard loop recorders versus 24-hour holter monitors for arrhythmia detection. Am J Cardiol, 95:1055–9. Ricci R, Quesada A, Pignalberi C, et al. 2004. Dual deﬁbrillator improves quality of life and decreases hospitalizations in patients with drug refrac- tory atrial ﬁbrillation. J Interv Card Electrophysiol, 10:85–92. Roijer A, Meurling CJ, Eskilsson J, et al. 2001. Left atrial appendage out- ﬂow velocity index is superior to conventional criteria for prediction of maintenance of sinus rhythm after cardioversion. Scand Cardiovas J, 35:119–24. Roy D, Talajic M, Dorian P, et al. 2000. Amiodarone to prevent recurrence of atrial ﬁbrillation. Canadian Trial of atrial ﬁbrillation investigators. N Engl J Med, 342:913–20. Seitelberger R, Hannes W, Gleichauf M, et al. 1994. Effects of diltiazem on perioperative ischemia, arrhythmias, and myocardial function in patients undergoing elective coronary bypass grafting. J Thorac Cardiovasc Surg, 107:811–21. Shinokawa N, Hirai T, Takashima S, et al. 2001. A transesophageal echocar- diographic study on risk factors for stroke in elderly patients with atrial ﬁbrillation: a comparison with younger patients. Chest, 120:840–6. Singer DE, Albers GW, Dalen JE, et al. 2004. Antithrombotic Therapy in atrial ﬁbrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 126:429S–56S. Stroke Prevention in atrial ﬁbrillation investigators. 1991. The Stroke Prevention in atrial ﬁbrillation (SPAF) study: ﬁnal results. Circula- tion, 84:527–539. Steeds RP, Birchall AS, Smith M, et al. 1999. An open label, randomised, crossover study comparing sotalol and atenolol in the treatment of symptomatic paroxysmal atrial ﬁbrillation. Heart, 82:170–5. Strasberg B, Arditti A, Sclarovsky S. 1985. Efﬁcacy of intravenous amio- darone in the management of paroxysmal or new atrial ﬁbrillation with fast ventricular response. Int J Cardiol, 7:47–55. Stewart S, Hart CL, Hole DJ, et al. 2001. Population prevalence, incidence, and predictors of atrial ﬁbrillation in the Renfrew/Paisley study. Heart, 86:516–21. Swancutt D, Hobbs R, Fitzmaurice D, et al. 2004. A randomised controlled trial and cost effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial ﬁbrillation in the over 65s: (SAFE). BMC Cardiovasc Disord, 4:12. Sudlow M, Rodgers H, Kenny RA, et al. 1998. Identiﬁcation of patients with atrial ﬁbrillation in generalpractice: a study of screening methods. BMJ, 317:327–8. Ueng KC, Tsai TP, Tsai CF, et al. 2001. Acute and long-term effects of atrioventricular junction ablation and VVIR pacemaker in symptomatic patients with chronic lone atrial ﬁbrillation and normal ventricular response. J Cardiovasc Electrophysiol, 12:303–9. Valencia MJ, Climent PV, Marin O, et al. 2002. The efﬁcacy of scheduled cardioversion in atrial ﬁbrillation: Comparison of two schemes of treatment: Electrical versus pharmacological cardioversion. Revista Espanola de Cardiologia, 55:113–20. van Walraven C, Hart RG, Singer DE, et al. 2002. Oral anticoagulants vs aspirin in nonvalvular atrial ﬁbrillation: an individual patient meta- analysis. JAMA, 288:2441–8. van Walraven C, Hart RG, Wells GA, et al. 2003. A clinical prediction rule to identify patients with atrial ﬁbrillation and a low risk for stroke while taking aspirin. Arch Intern Med, 163:936–43. Van Gelder IC, Hagens VE, Bosker HA, et al. 2002. A comparison of rate control and rhythm control in patients with recurrent persistent atrial ﬁbrillation. N Engl J Med, 347:1834–40. Vecht RJ, Nicolaides EP, Ikweuke JK. 1986. Incidence and prevention of supraventricular tachyarrhythmias after coronary bypass surgery. Int J Cardiol, 13:125–34. Wang HE, O’connor RE, Megargel RE, et al. 2001. The use of diltiazem- for treating rapid atrial ﬁbrillation in the out-of-hospital setting. Ann Emerge Med, 37:38–45. Wazni OM, Marrouche NF, Martin DO, et al. 2005. Radiofrequency ablation vs antiarrhythmic drugs as ﬁrst-line treatment of symptomatic atrial ﬁbrillation: A randomized trial. JAMA, 293:2634–40. Wolf PA, Benjamin EJ, Belanger AJ, et al. 1996. Secular trends in the prevalence of atrial ﬁbrillation: the Framingham study. Am Heart J, 131:790–5. Wolf PA, Belanger AJ, Kannel WB, et al. 1991. Probabilty of stroke: A risk proﬁle from Framingham study. Stroke, 22:312–8. Wolf PA, Kannel WB, McGee DL, et al. 1983. Duration of atrial ﬁbrillation and imminence of stroke: the Framingham study. Stroke, 14:664–7. Wyse DG, Waldo AL, DiMarco JP, et al. 2002. A comparison of rate control and rhythm control in patients with atrial ﬁbrillation. N Engl J Med, 347:1825–33. Zariﬁs J, Beevers G, Lip GY. 1997. Acute admissions with atrial ﬁbrillation in a British multiracial hospital population. Br J Clin Pract, 51:91–6. 116 Vascular Health and Risk Management 2007:3(1)